• LAST PRICE
    0.0749
  • TODAY'S CHANGE (%)
    Trending Down-0.0033 (-4.1613%)
  • Bid / Lots
    0.0720/ 278
  • Ask / Lots
    0.0777/ 539
  • Open / Previous Close
    0.0694 / 0.0781
  • Day Range
    Low 0.0668
    High 0.0777
  • 52 Week Range
    Low 0.0514
    High 0.2900
  • Volume
    33,330
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 0.0781
TimeVolumeGRTX
09:32 ET15000.0694
09:36 ET10500.0668
09:43 ET72540.0668
09:50 ET17040.07315
09:54 ET5000.0686
09:56 ET5000.0686
09:57 ET20000.07458
10:03 ET70490.073
10:10 ET46000.0777
10:26 ET4230.07622
10:28 ET3000.07485
10:35 ET11000.072
10:37 ET12560.07428
10:39 ET30000.07542
11:08 ET10000.07485
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesGRTX
Galera Therapeutics Inc
4.2M
-0.1x
---
United StatesENVB
Enveric Biosciences Inc
4.2M
-0.1x
---
United StatesKTTA
Pasithea Therapeutics Corp
4.1M
-0.3x
---
United StatesSNPX
Synaptogenix Inc
4.1M
-0.8x
---
United StatesTCBP
TC Biopharm (Holdings) PLC
3.3M
0.0x
---
United StatesCELZ
Creative Medical Technology Holdings Inc
4.1M
-0.8x
---
As of 2024-09-25

Company Information

Galera Therapeutics, Inc. is a biopharmaceutical company focused on developing a pipeline of novel, therapeutic candidates that have the potential to transform radiotherapy in cancer. The Company’s lead product candidate, avasopasem manganese (avasopasem), is a highly selective small molecule dismutase mimetic that the Company is developing for the reduction of severe oral mucositis (SOM) in patients with head and neck cancer (HNC), the reduction of esophagitis in patients with lung cancer, and the reduction of cisplatin-induced kidney damage in patients with cancer. The Company’s second product candidate, rucosopasem manganese (rucosopasem), is in development to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. Rucosopasem is an orphan drug designation and orphan medicinal product designation for the treatment of pancreatic cancer.

Contact Information

Headquarters
45 Liberty Blvd., Suite 230MALVERN, PA, United States 19355
Phone
610-725-1500
Fax
302-636-5454

Executives

Independent Chairman of the Board
Michael Powell
President, Chief Executive Officer, Director
J. Mel Sorensen
Chief Legal & Compliance Officer, Secretary
Jennifer Stacey
Independent Director
Lawrence Alleva
Independent Director
Emmett Cunningham

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$4.2M
Revenue (TTM)
$0.00
Shares Outstanding
54.4M
Galera Therapeutics Inc does not pay a dividend.
Beta
1.95
EPS
$-0.59
Book Value
$-2.41
P/E Ratio
-0.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.